Meta-analysis: Potentials and promise

BMJ

Volumn 315, Issue 7119, 1997, Pages 1371-1374

  Egger, Matthias ^a   Smith, George Davey ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; META ANALYSIS; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS;

META-ANALYSIS;

EID: 0030711655     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.315.7119.1371     Document Type: Article

References (47)

1. Naylor CD. Meta-analysis and the meta-epidemiology of clinical research. BMJ 1997; 315: 617–9.
2. Bailar JC. The promise and problems of meta-analysis [editorial]. N Engl J Med 1997; 337: 559–61.
3. Meta-analysis under scrutiny [editorial]. Lancet 1997; 350: 675.
4. Huque MF. Experiences with meta-analysis in NDA submissions. Proceedings of the Biopharmaceutical Section of the American Statistical Association 1988; 2: 28–33.
5. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev 1992; 14: 154–76.
6. Chalmers I, Altman DG. Foreword. In: Chalmers I, Altman DG, eds. Systematic reviews. London: BMJ Publishing, 1995.
7. Egger M, Davey Smith G, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997 (in press).
8. Davey Smith G, Egger M, Phillips AN. Meta-analysis: beyond the grand mean? BMJ 1997 (in press).
9. Egger M, Davey Smith G. Meta-analysis: bias in location and selection of studies. BMJ 1997 (in press).
10. Egger M, Schneider M, Davey Smith G. Meta-analysis: spurious precision? Meta-analysis of observational studies. BMJ 1997 (in press).
11. Davey Smith G, Egger M. Meta-analysis: unresolved issues and future developments. BMJ 1997 (in press).
12. Pearson K. Report on certain enteric fever inoculation statistics. BMJ 1904; 3: 1243–6.
13. Beecher HK. The powerful placebo. JAMA 1955; 159: 1602–6.
14. Glass G. Primary, secondary and meta-analysis of research. Educ Res 1976; 5: 3–8.
15. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progr Cardiovasc Dis 1985; 17: 335–71.
16. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319: 1681–92.
17. Chalmers I, Enkin M, Keirse M. Effective care during pregnancy and childbirth. Oxford: Oxford University Press, 1989.
18. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiologic Reviews 1987; 9: 1–30.
19. General Accounting Office. Cross design synthesis: a new strategy for medical effectiveness research. Washington D.C.: G.O.A. 1992.
20. Cross design synthesis: a new strategy for studying medical outcomes [editorial]? Lancet 1992; 340: 944–6.
21. Chalmers I, Dickersin K, Chalmers TC. Getting to grips with Archie Cochrane's agenda. BMJ 1992; 305: 786–8.
22. Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995; 274: 1935–8.
23. Chalmers TC, Frank CS, Reitman D. Minimizing the three stages of publication bias. JAMA 1990; 263: 1392–5.
24. Oakes M. Statistical inference: a commmentary for the social and behavioural sciences. Chichester: Wiley, 1986.
25. Nurmohamed MT, Rosendaal FR, Bueller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152–6.
26. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913–20.
27. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1449–61.
28. Götzsche PC, Podenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. J Clin Epidemiol 1992; 45: 587–94.
29. Teagarden JR. Meta-analysis: whither narrative review? Pharmacotherapy 1989; 9: 274–84.
30. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992; 305: 15–9.
31. Götzsche PC. Reference bias in reports of drug trials. BMJ 1987; 295: 654–6.
32. Mulrow CD. The medical review article: state of the science. Ann Intern Med 1987; 106: 485–8.
33. Cooper HM, Rosenthal R. Statistical versus traditional procedures for summarising research findings. Psychol Bull 1980; 87: 442–9.
34. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error, and sample size in the design and interpretation of the randomized controlled trial. In: Bailar JC, Mosteller F, eds. Medical uses of statistics. Boston, MA: NEJM Books, 1992: 357.
35. Collins R, Keech A, Peto R, Sleight P, Kjekshus J, Wilhelmsen L, et al. Cholesterol and total mortality: need for larger trials. BMJ 1992; 304: 1689.
36. Jenicek M. Meta-analysis in medicine. Where we are and where we want to go. J Clin Epidemiol 1989; 42: 35–44.
37. Gelber RD, Goldhirsch A. Interpretation of results from subset analyses within overviews of randomized clinical trials. Stat Med 1987; 6: 371–8.
38. Chalmers I. Randomised controlled trials of fetal monitoring 1973-1977. In: Thalhammer O, Baumgarten K, Pollak A, eds. Perinatal medicine. Stuttgart: Thieme, 1979: 260.
39. Mac Donald D, Grant A, Sheridan-Pereira M, Boylan P, Chalmers I. The Dublin randomised controlled trial of intrapartum fetal heart rate monitoring. Am J Obstet Gynecol 1985; 152: 524–39.
40. Rosenthal R. An evaluation of procedures and results. In: Wachter KW, Straf ML, eds. The future of meta-analysis. New York: Russel Sage Foundation, 1990: 123.
41. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248–54.
42. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 397–402.
43. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349–60.
44. Mitchell JRA. Timolol after myocardial infarction: an answer or a new set of questions? BMJ 1981; 282: 1565–70.
45. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA 1992; 268: 240–8.
46. Murphy DJ, Povar GJ, Pawlson LG. Setting limits in clinical medicine. Arch Intern Med 1994; 154: 505–12.
47. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.